Abstract
Background: Prior studies have demonstrated an association between appropriate implantable cardioverter defibrillator (ICD) shocks and mortality in clinical trials. The effect of shock burden on heart failure and mortality has not been previously studied in a large population-based cohort. Methods: The cohort was derived using a comprehensive prospective ICD registry in the province of Nova Scotia with a mean follow-up of 4 ± 2.3 years. With the use of time-varying analysis, the relationship among shock burden, mortality, and heart failure hospitalization was determined. Results: A total of 776 patients (mean age of 64.8 years) were included in the study, of whom 37% received appropriate therapy during follow-up. A single ICD shock did not confer an increased mortality risk compared with no therapy (hazard ratio [HR], 1.23; 95% confidence interval [CI], 0.84-1.79; P = 0.3), but mortality risk was significantly increased with ≥ 2 shocks (HR, 3.23; 95% CI, 2.04-5.09; P < 0.0001). There was a significant increase in heart failure hospitalization associated with receiving 1 ICD shock (HR, 2.05; 95% CI, 1.46-2.89; P < 0.0001) or more than 1 ICD shock (HR, 4.36; CI, 2.53-7.52; P < 0.0001) compared with patients receiving no ICD therapy. Patients who received antitachycardia pacing alone showed no difference in heart failure hospitalization (HR, 0.93; CI, 0.67-1.29; P = 0.7) and improved survival (HR, 0.69; CI, 0.5-0.96; P = 0.03) compared with those receiving no ICD therapy. Conclusion: Ventricular arrhythmia treated with appropriate ICD shocks is associated with an increased risk of heart failure hospitalization, whereas recurrent episodes of ventricular arrhythmia requiring shocks are associated with both higher mortality and higher heart failure hospitalization rates.
Original language | English |
---|---|
Pages (from-to) | 161-167 |
Number of pages | 7 |
Journal | CJC Open |
Volume | 1 |
Issue number | 4 |
DOIs | |
Publication status | Published - Jul 2019 |
Bibliographical note
Funding Information:Dr Sapp has received research funding from Biosense Webster and St. Jude Medical, and consulting fees/honoraria from St Jude Medical, Medtronic, and Biosense Webster. Dr AbdelWahab has received honoraria from St Jude Medical, Medtronic, and Biosense Webster. Dr Parkash has received consulting fees/honoraria/salary from Medtronic, St Jude Medical, Bayer Canada, and Pfizer Canada. The other authors report no conflicts of interest.
Funding Information:
This study is supported by the Cardiac Arrhythmia Network and the Nova Scotia Health Authority Research Fund.
Publisher Copyright:
© 2019 Canadian Cardiovascular Society
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine
PubMed: MeSH publication types
- Journal Article